Kornimate/medical-research-clean huggingface dataset:
the effect of nutrition counseling on nutritional status in stroke patients

Conditions: Stroke, Acute; Malnutrition; Old Age; Debility

Summary: the purpose of this study is to investigate the effect of intensive nutrition counseling on nutritional status and functional recovery in stroke patients over the age of 65, compared to standard nutrition counseling.

stroke is the second most common cause of death in the world; it is the third cause of disability that causes serious loss of function and affects patients' daily activities. the rapid aging of society increases the negative impact of stroke on health and limited health resources. 9-35% of patients hospitalized with the diagnosis of acute stroke have malnutrition. however, in the first two weeks after hospitalization, malnutrition rates approximately double within two weeks of hospitalization. although nutrition is a physiological need, it is also a social activity. nutritional practices that meet nutritional needs during the disease process may contribute to the functional recovery of patients, the reduction of complications, and survival, as well as contributing to the quality of life of patients, independent of the disease. in terms of malnutrition risk, monitoring and treatment are recommended during the acute and discharge periods. there is a need for studies on the framework and effects of effective nutritional treatment. in order for nutrition treatment practices after discharge to achieve their goals, caregivers need to be trained effectively on this subject. therefore, the aim of this study is to examine the effects of intensive nutrition counseling to stroke patients over the age of 65 on nutritional and functional status.

Eligibility criteria:
inclusion criteria: * being admitted to ege university faculty of medicine hospital neurology intensive care or clinic with the diagnosis of acute stroke * the patient agrees to participate in the study * hospital stay for more than 3 days exclusion criteria: * active malignancy, dementia, terminal illness, tetraplegia, severe metabolic disorder * failure to obtain written consent indicating that they agreed to participate in the study. * the patient did not come for a check-up during the 3-month follow-up period * the patient's stay is longer than 30 days

Keywords: malnutrition older
efficacy and safety of h.p. acthar gel in adults with retinal vasculitis

Conditions: Uveitis, Posterior; Vasculitis Retinal

Summary: the purpose of this study is to evaluate the short- and long-term efficacy and safety of acthar for the treatment of adults with non-infectious retinal vasculitis.


Eligibility criteria:
inclusion criteria: * any adult patient with active retinal vasculitis (involving arteries or veins) as a manifestation of non-infectious ocular inflammatory disease; fundus must be viewable with wide-field fa in the study eye * if both eyes are involved, both are eligible for inclusion in the study * patients already on non-steroidal immunosuppressive therapy may continue on this during the study, but the dose must not be increased or decreased within 6 weeks of initiating the trial * willing and able to sign the informed consent form exclusion criteria: * patients under age 18 * patients who are pregnant (must be ruled out in women of child-bearing age) * active infectious ocular or systemic disease * patients with active infectious ocular or extraocular disease * patients with history of malignancy, except for dermatologic entities of basal or squamous cell carcinoma which have been completely excised or removed previously * patients with systemic illness involving abnormalities of the hypothalamic-pituitary-adrenal axis; patients with primary adrenocortical insufficiency or adrenocortical hyperfunction * patients with known hypersensitivity to acthar * patients on other non-steroidal systemic immunomodulatory medications with dose adjusted sooner than 6 weeks prior to study drug administration * patients currently on or recently treated with (within 6 weeks) systemic corticosteroid * patients with periocular or intraocular injections of medications administered to help control inflammation sooner than 6 weeks prior to study drug administration * patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator, or contraindicated, including but not limited to, patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, or sensitivity to proteins of porcine origin. administration of live or live attenuated vaccines is contraindicated in patients during the entire duration of the study and for one month prior
ct 327 in the treatment of psoriasis vulgaris

Conditions: Psoriasis

Summary: this study will look at how safe and effective, a novel agent, ct 327 cream is in treating patients with mild to moderate psoriasis vulgaris (pv). patients will be treated twice daily for 8 weeks on specific lesions of pv and safety and symptoms of pv will be assessed throughout the treatment period.


Eligibility criteria:
inclusion criteria: * age \> 18 and \< 71 years of age * able to give informed consent * diagnosis of mild (affecting \< 3% bsa) to moderate (affecting \< 10% bsa) psoriasis vulgaris, including, at baseline visit, two symmetrical lesions of at least 10 cm2 each exclusion criteria: * if female of childbearing potential not using an adequate and appropriate form of contraception such as oral contraceptive; intra-uterine device (iud); contraceptive injection, implant or patch * if female, are pregnant or lactating, or intend to become pregnant during the study period and one month thereafter * allergy to test drug or excipients * usage of topical corticosteroids or other topical treatments for pv within the last two weeks prior to study entry (including calcineurin inhibitor, topical h1 antihistamines, topical antimicrobials, other medicated topical agents) or herbal preparation to the area selected for treatment within 4 weeks prior to study entry, have received systemic treatment for psoriasis (including systemic corticosteroids, nonsteroidals, immunosuppressants, or immunomodulating drugs, or treatment with light). * received treatment with systemic or locally acting medications which might counter or influence the study aim * presence of major medical illness requiring systemic therapy including cancers * clinical diagnosis of bacterial infection of the skin including impetigo and abscesses * any clinical relevant ecg abnormality * have any clinically significant abnormal clinical laboratory test results at screening * received any investigational drug or taking part in any clinical study within three months prior to this study * history of drug, alcohol or other substance abuse or other factors limiting the ability to co-operate and to comply with this protocol * have concomitant dermatologic or medical condition(s) which may interfere with the investigator's ability to evaluate the subject's response to the study drug * have immune-compromised status (such as known human immunodeficiency virus infection) * have a history of malignancy, excluding basal cell carcinoma of the skin * have an active intercurrent infection * suffer from erythrodermic psoriasis, psoriasis punctata and pustular psoriasis or extended chronic stationary forms of psoriasis * have symptoms of a clinically significant illness that may influence the outcome of the study * have any reason which, in the opinion of the investigator, interferes with the ability of the subject to participate in or complete the trial, or which places the subject at undue risk

Keywords: mild to moderate psoriasis vulgaris
efavirenz and lamivudine/zidovudine for treatment-naive hiv infected adults in senegal

Conditions: HIV Infections

Summary: the purpose of this study is to determine the safety and effectiveness of the anti-hiv drugs efavirenz and lamivudine/zidovudine given to treatment-naive hiv-infected people in dakar, senegal.

despite a relatively low prevalence of hiv infection, all hiv subtypes have been documented in senegal. data on mutations that confer resistance to antiretroviral (arv) drugs are limited to hiv subtype b; adherence data are also limited. the study will evaluate the safety and efficacy of an arv regimen given to treatment-naive hiv infected adults and adolescents. the study will also examine the characteristics of virologic failure and adherence in this treatment group. participants will be recruited at two sites in dakar, senegal. this study will last 96 weeks. at study entry, all participants will be given an arv regimen of lamivudine/zidovudine twice daily and efavirenz once daily. if toxicity or treatment failure occurs, some participants may require changes in their arv regimens. there will be 14 study visits during the study; a physical exam, blood collection, and sociodemographic and medication history assessments will occur at each visit. participants will also be asked to complete quality-of-life and adherence questionnaires. an off-study visit will occur at approximately one month after week 96, with assessments and procedures similar to visits during the study.

Eligibility criteria:
inclusion criteria: * hiv-infected * have never taken arv drugs * cd4 count of 200 cells/mm3 or less within 30 days of study entry if asymptomatic or cd4 count of 350 cells/mm3 or less within 60 days of study entry if cdc category a or b clinical condition present or clinical diagnosis of aids, regardless of cd4 count * willing to stay in the study area for the duration of the study * willing to use acceptable forms of contraception exclusion criteria: * hiv-2 infected * systemic chemotherapy (except interferon) within 6 months prior to study entry * current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study * serious illness, including any active aids-defining infection, active tuberculosis, malaria, or any illness requiring systemic treatment or hospitalization. people who have completed therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded. * serious psychiatric problems within 60 days of study entry, including depression, suicidal thoughts or attempts, aggressive behavior, or psychosis-like symptoms * have taken certain medications within 30 days of study entry * pregnancy or breastfeeding

Keywords: treatment naive
reversal of tobacco-related sinusitis

Conditions: Rhinosinusitis

Summary: this study is focused on identifying the prevalence of passive or active smoke exposure and zinc deficiency in a cohort of patients who meet the objective and subjective guidelines for chronic rhinosinusitis set forth by the sinus and allergy health partnership.

by using patient screening questionnaires and measuring hair nicotine, a well acknowledged biomarker of exposure to tobacco smoke, we will attempt a more objective study to examine the association between tobacco smoke and chronic rhinosinusitis. (crs) likewise, zinc deficiency is documented in numerous animal and human studies to decrease resistance to infectious diseases and is especially common among smokers. we will explore our hypothesis that shs exposure and zinc deficiency contribute to crs. to accomplish this, we will measure serum zinc and hair nicotine levels in crs patients and correlate them to a variety of crs diagnostic indicators. a second objective of this study is investigating alterations within the epithelium lining the sinonasal cavities in patients with chronic rhinosinusitis. the alterations may be one or a combination of anatomic, genetic, inflammatory, or infectious etiologies. to further investigate these possibilities we plan on taking residual clinical material from endoscopic sinus surgery specimens and performing various in vitro investigations including but not limited to microarray analysis, northern and western blot analysis, ciliary beat frequency analysis, immunohistochemistry, electron microscopy, and propagation of tissue with tissue culture techniques. tissues taken from non-sinusitis patients undergoing sinonasal surgery will serve as a non-chronic rhinosinusitis control source of sinus mucosa.

Eligibility criteria:
inclusion criteria: * crs and skull base surgery patients; crs patients that meet the objective and subjective guidelines for crs set forth by the sinus and allergy health partnership. exclusion criteria: * ciliary dysfunction, autoimmune disease, cf or any known immunodeficiency.
brief interventions to create smoke-free home policies in low-income households

Conditions: Chronic Diseases

Summary: the burden of tobacco use falls disproportionately on low-income populations, through high rates of primary smoking and exposure to secondhand smoke. the remarkable progress in creating smoke-free environments in the u.s. over the past two decades has left smoker's homes as one of the primary sources of exposure to secondhand smoke for both children and nonsmoking adults. intervention research that identifies effective and practical strategies for reaching the minority of households that still allow smoking in the home has considerable potential to reduce smoke exposure, but suitable channels to reach low-income families are limited. the proposed research will develop, evaluate and disseminate a brief smoke-free homes intervention through the established national infrastructure of 2-1-1 call centers. 2-1-1 is a nationally designated 3-digit telephone exchange, similar to 9-1-1 for emergencies or 4-1-1 for directory assistance, that links callers to community-based health and social services. the proposed research has four specific aims: 1) conduct formative research on intervention messages and materials for promoting smoke-free homes in low-income populations, applicable to both smokers and nonsmokers as household change agents; 2) conduct a randomized controlled trial in the atlanta 2-1-1 service area to evaluate the efficacy of a brief intervention to create smoke-free homes among 2-1-1 callers; 3) conduct replication studies in houston and north carolina 2-1-1 systems to systematically test the intervention in varied populations and tobacco control climates, and 4) disseminate the research-tested smoke-free homes intervention through a variety of mechanisms including a national grants program to 2-1-1 systems and through the tobacco technical assistance consortium's linkages to the state and local tobacco control infrastructure in the u.s.


Eligibility criteria:
inclusion criteria: * must be 18 years of age or older. * must speak and understand english. * must smoke and live with at least one other non-smoking person or be a non-smoker who lives with a smoker(s). * must not have a total smoking ban in their home. exclusion criteria: * none

Keywords: secondhand smoke exposure smoke-free homes smoke-free home bans
comparison of small colorectal polyp removal using cold emr with hot emr

Conditions: Colonic Polyps

Summary: this study evaluates the efficacy of small colorectal polyp removal using cold endoscopic mucosal resection with hot endoscopic mucosal resection. half of the participants will receive cold endoscopic mucosal resection, while the other half will receive hot endoscopic mucosal resection.

colorectal polyps are considered as precancerous lesions and endoscopical resection is currently the treatment of choice when it is possible. colorectal polyps are classified into diminutive polyps (\ 1cm in diameter). there are several endoscopical treatment methods: cold biopsy forceps polypectomy, cold snare polypectomy, hot biopsy forceps polypectomy, hot snare polypectomy, and endoscopic mucosal resection. cold polypectomy means mechanical removal of the polyp with snare or biopsy forceps without the use of electrocautery, and hot polypectomy means removal of the polyp with the use of electocautery.

Eligibility criteria:
inclusion criteria: * patients with colorectal polyps that are \<1cm in diameter who need endoscopic mucosal resection. * patients who gave informed consents to this study. exclusion criteria: * patients under the age of 19 * patients who are receiving antiplatelet or anticoagulant therapies * patients with hypercoagulability (i.e., liver cirrhosis, hemophilia, end-stage renal disease, or chronic kidney disease)

Keywords: colonic polyps endoscopic mucosal resection colonoscopy
identification of viruses associated with diseases of unknown cause

Conditions: Viral Diseases

Summary: this study will try to identify new or known viruses responsible for diseases or conditions of unknown cause. viruses are an important cause of illness. they have been identified as causes of several cancers, including certain liver cancers and cervical cancer. several diseases, such as kawasaki s disease, aplastic anemia, aphthous ulcers, and certain fevers of unknown origin in immune suppressed patients are thought possibly to be due to viruses, but their cause has not yet been determined. this study will use very sensitive molecular techniques to try to identify new or known viruses in patients with conditions of unknown causes. this study does not involve any treatment. any patient with a condition or disease whose cause is unknown may be eligible for this study. a referral from a local physician is required for patients who wish to enroll in this study. participants will have blood samples drawn up to four times during the study. the total amount of blood drawn in any 6-week period will not exceed 50 milliliters (about 3-1/2 tablespoons) for adults and 5 ml (about 1/2 tablespoon) per kilogram (2.2 pounds) for children. in addition, body fluids, such as joint or spinal fluid, or tissue samples, such as biopsy specimens, obtained previously for medical purposes, may be obtained for testing. the patient s doctor will be informed of any positive findings from the samples. identification of a virus does not necessarily mean that the virus is causing the patient s condition or disease. additional tests from many patients with similar diseases or conditions are required before a virus can be definitively associated with a disease. similarly, failure to find a virus does not necessarily mean that the patient is not infected with a virus that is causing the condition, as the tests used in this study are imperfect and will not detect certain forms of viruses that can cause disease.

viral infections are an important cause of morbidity and mortality in hospitalized patients. viruses have also been identified as the probable cause of a number of malignancies including hepatocellular carcinoma and cervical carcinoma. the purpose of this study is to identify novel viruses (or known viruses) that are associated with diseases whose etiology is unknown. blood samples, body fluids, or discarded tissues (e.g. previous biopsy or autopsy material) saliva swabs, nasopharyngeal swabs, skin biopsies, or mucosal biopsies will be obtained from patients with clinical syndromes or diseases whose etiology is unknown. highly sensitive assays using the polymerase chain reaction will be performed to attempt to identify novel or known viruses that might be present in the blood, body fluids, or tissues. knowledge gained from this study could provide important insights into the cause of diseases whose etiology is presently unknown.

Eligibility criteria:
* inclusion criteria: any patient with a condition or disease whose etiology is unknown. adequate venous access. exclusion criteria: none

Keywords: polymerase chain reaction random priming nucleic acid viral genome
effect of benzydamine hydrochloride to postoperative sore throat in pediatric patients

Conditions: Intubation Complication

Summary: this study is designed to examine the effect of benzydamine hydrochloride to postoperative sore throat in pediatric patients. we will spray benzydmaine hydrochloride or normal saline at oral cavity and the tip of endotracheal tube, than compare the prevalence of postoperative sore throat using smartphone application in pediatric patients.

1. postoperative sore throat incidence (over 2) 1; no, 2;mild, 3;moderate, 4;severe 2. scoring of pain with smartphone application (kids pain scale) 3. incidence of use of rescue pain killer

Eligibility criteria:
inclusion criteria: * general anesthesia * intubation require exclusion criteria: * recent upper airway infection * could not express the pain
bioequivalence of lb80380 free base and maleate salt tablets

Conditions: Hepatitis B

Summary: the study is to compare pharmacokinetics of lb80331 and lb80317, which are the metabolites of lb80380, after a single oral administration of lb80380 free base 150 mg (60 mg + 90 mg) tablet or lb80380 maleate tablet 183 mg (150 mg as a free base) in healthy male subjects.


Eligibility criteria:
inclusion criteria: * male with good health * 20 to 45 years of age at screening * body weight ±20% of ideal body weight * willingness and ability to comply with study procedures and communicate with investigators * provided written consent voluntarily after informed of all the pertinent aspects of the trial exclusion criteria: * clinically significant abnormality on medical interview, physical examination, electrocardiogram or clinical laboratory evaluations * clinically significant acute or chronic medical conditions * use of prescriptive medicine within 14 days, or over-the-counter drug within 7 days before the first day of drug administration * participation in clinical trial within 3 months before the first day of drug administration * alcohol abuse * habitual smoker * habitual user of herbal medicine * use of grapefruit-containing food or grapefruit juice during the study period * positive drug abuse test and positive hbs-antigen, hcv-antibody, or hiv-antibody test

Keywords: lb80380 bioequivalence
hyponatremia registry for patients with euvolemic and hypervolemic hyponatremia

Conditions: Euvolemic Hyponatremia; Hypervolemic Hyponatremia

Summary: the registry is a multi-center, prospective, observational study designed to collect data in patients with euvolemic and hypervolemic hyponatremia in the hospital setting in the usa and hyponatremia secondary to syndrome of inappropriate antidiuretic hormone secretion (siadh) in europe; patients with hypovolemic hyponatremia will be excluded from the registry. the registry is observational in design, and the registry will collect data on patients with a serum sodium ≤130 mmol/l. data from the patients' chart will be collected throughout the duration of the hospital, from admission to discharge, and the data will be entered into the case report form (crf) or into an electronic data capture (edc) system. these patients will be entered into the registry over the duration of 18 months at community, tertiary, and academic medical centers from diverse multiple regions of the usa and europe. a patient's treatment will be determined by their caregiver and not by this protocol. thus, the registry will provide a unique opportunity to evaluate how the patients are managed under real-world management conditions.


Eligibility criteria:
inclusion criteria: * adults ≥18 years old who are hospitalized * euvolemic or hypervolemic hyponatremia with serum sodium ≤130mmol/l * for euvolemic hyponatremia: * euvolemia is defined as: absence of clinical and historical evidence of extracellular fluid volume depletion or sequestration; and absence of edema and ascites; or * physician diagnosis of siadh * for hypervolemic hyponatremia (applies to usa sites only): * hypervolemia is defined as: excess extracellular fluid volume manifesting as dependent edema or ascites * patients may have one or more of the following underlying co-morbid conditions: * congestive heart failure * cirrhosis and/or liver failure * nephrotic syndrome exclusion criteria: * patients with hypovolemic hyponatremia * use of investigational drug, biologic, or device during the study

Keywords: hyponatremia euvolemia hypervolemia euvolemic hypervolemic